著者 |
田中 小百合
島根大学医学部内科学第一
金沢 一平
島根大学医学部内科学第一
野津 雅和
島根大学医学部内科学第一
杉本 利嗣
島根大学医学部内科学第一
|
内容記述(抄録等) | OBJECTIVE: The relationship between serum DPP-4 level and visceral fat mass is still unclear in type 2 diabetes mellitus (T2DM). This study thus aimed to examine the association of visceral fat accumulation and metabolic syndrome with serum DPP-4 levels in T2DM.
METHODS: Visceral and subcutaneous fat areas were evaluated by performing computed tomography scan in 135 men with T2DM, who had never taken DPP-4 inhibitors or GLP-1 receptor agonists. We investigated the association between serum DPP-4 levels and visceral fat area as well as the presence of metabolic syndrome. RESULTS: Multiple regression analysis adjusted for age, duration of T2DM, body mass index, serum creatinine, and HbA1c showed that serum DPP-4 levels were positively associated with visceral fat area (β=0.25, p=0.04), but not subcutaneous fat area (β=-0.18, p=0.13). In logistic regression analyses adjusted for the confounding factors described above, serum DPP-4 levels were positively associated with visceral fat obesity and metabolic syndrome [odds ratio (OR)=1.63, 95% confidence interval (CI)=1.00-2.66 per standard deviation (SD) increase, p=0.04; OR=1.77, 95%CI=1.09-2.88 per SD increase, p=0.02, respectively]. CONCLUSIONS: The present study showed that serum DPP-4 level was positively and specifically associated with accumulation of visceral fat and the presence of metabolic syndrome in men with T2DM. |
主題 | Dipeptidyl peptidase-4
Visceral fat
Metabolic syndrome
Type 2 diabetes mellitus
|
掲載誌情報 |
Diabetes research and clinical practice
116
, 1
- 6
, 2016-06
|
出版者 | Elsevier
|
権利関係 | © 2016 Elsevier Ireland Ltd. All rights reserved.
|